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Abstract
Uterine sarcomas (USs) account for 3–9% of uterine malignant neoplasia and about 5% 
of all gynaecologic malignancies. Despite their low prevalence, these tumors stimulate 
a great interest because of their aggressiveness, poor prognosis and high mortality rate. 
According to the last world health organization (WHO) classification and the International 
Federation of gynecology and obstetrics committee (FIGO) staging, USs are categorized 
as pure mesenchymal tumors (endometrial stromal sarcoma, leiomyosarcoma and undif-
ferentiated uterine) and mixed tumors (carcinosarcoma and adenosarcoma). Due to their 
non-specific signs and symptoms, USs are commonly diagnosed in advanced stage, more 
often after surgery for a suspected leiomyoma. Although surgery followed by adjuvant 
therapies represent the common choices for USs, they show poor efficacy due to the early 
occurrence of metastasis, and the high resistance of tumors to radio-and chemotherapy. 
Presently, specific expression profiles and new cytotoxic agents are under investigation. 
In these reviews, we summarized clinical and pathological features, imaging characteris-
tics, therapeutic approaches, genomic and molecular aberration associated with smooth 
muscle neoplasia (Part 1) and endometrial stromal neoplasia (Part 2); the goal is to under-
stand the biology and the molecular signature of these tumors, in order to focus on their 
best management.
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uterine stromal sarcomas
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1. Introduction
Endometrial stromal sarcomas (ESSs) are mesenchymal malignancies mainly occurring in 
uterine corpus. Alternative origins, such as ovary and peritoneum, have been described. 
Pathogenesis of ESSs has been widely debated. The rarity of this neoplasia contributed to the 
difficulty in classifying them into clinically meaningful categories. All started in 1966 with 
Norris and Taylor, who classified ESS into low-grade and high-grade neoplasia, basing on the 
degree of mitotic activity [1]. Following studies demonstrated the irrelevant value of mitotic 
activity as prognostic factor. In 1982, Evans understood the importance of separating tumors 
with endometrial stromal differentiation from poorly differentiated endometrial sarcoma [2]. 
Studies from Chang et al. demonstrated that a combined assessment of cytological/nuclear 
atypia and mitotic index could better provide prognostic information than either feature 
alone [3].
In 2003, WHO abolished “high-grade” category and adopted a classification based on two 
categories: low-grade ESS (histological resembling proliferative endometrial stroma) and 
undifferentiated endometrial sarcoma (UES) [4]. The main perplexity with 2003 WHO clas-
sification was related to the heterogeneity of undifferentiated endometrial sarcomas category, 
which enclosed tumors with different morphology, clinical behavior and outcome. In the 
following years, cytogenetic and molecular investigations helped to redefine ESSs and, in 
FIGO stage Definition
I Tumor limited to uterus
IA Tumor limited to endometrium/endocervix with no myometrial invasion
IB Less than or equal to half myometrial invasion
IC More than half myometrial invasion
II Tumor extended to the pelvis
IIA Adnexal involvement
IIB Tumor extends to extrauterine pelvic tissue
III Tumor invades abdominal tissues (not just protruding into the abdomen)
IIIA One site
IIIB More than one site
IIIC Metastasis to pelvic and/or paraaortic lymph nodes
IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases
IVA Tumor invades bladder and/or bowel mucosa
IVB Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes
FIGO, International Federation of Gynecology and Obstetrics Committee.
Table 1. 2009-revised FIGO staging system for endomerial stromal sarcomas.
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2014, WHO identified four groups of endometrial stromal neoplasia: endometrial stromal 
nodule-ESN, low-grade endometrial stromal sarcoma-LGESS, high-grade endometrial stro-
mal sarcoma-HGESS, and undifferentiated uterine sarcoma-UUS [5]. Each one demonstrated 
peculiar molecular signatures, morphological characteristics, and prognosis. FIGO staging 
system ESSs was revised in 2009 (Table 1) [6].
Endometrial stromal sarcoma accounts for approximately 10% of all uterine sarcomas and 
about 0.2% of all uterine malignant neoplasia. At presentation, the vast majority of patients 
are in the fifth decade; among these, about 50% are premenopausal women [7]. Although 
molecular mechanisms involved in the genesis of ESSs are not clear yet, obesity, diabetes, 
early menarche, and tamoxifen intake have been associated with an increased risk of develop-
ing this neoplasia [8]. Abnormal uterine bleeding and pelvic/abdominal pain represent the 
main symptoms of ESSs, which may be present as uterine mass or endometrial polyp. In the 
latter cases, endometrial biopsy is more likely to be diagnostic [8]. ESS may most often be 
an incidental finding in patients undergoing hysterectomy for other reasons; in such cases, 
pulmonary metastases may be detected at the time of the diagnosis [8].
2. Endometrial stromal nodule (ESN)
ESNs are defined as benign stromal tumors of the uterus. They occur in women ranging from 
31 to 86 years, with a mean of about 50 years [9].
2.1. Macroscopic features
ESNs are more common in uterine corpus than in the cervix. They show well defined but 
expansible margins, absent/minimal myometrial invasion, and no lymph vascular inva-
sion. If myometrial or lymph vascular invasions are present, tumor should be diagnosed as 
LGESS. ESN may occur as an intramural mass centered in the myometrium, or as a polypoid 
tumor protruding into the endometrial cavity [8]. On gross examination, ESN size ranges from 
1 to 22 cm. The nodule is well demarcated, even if finger-like projections (<3 in number and 
<3 mm in maximum extension) into adjacent myometrium may occur. In these cases, some 
pathologists diagnose this neoplasia as “endometrial stromal nodule with limited myometrial 
infiltration” [8]. The tumor shows a uniform tan-to-yellow soft cut surface; cysts formation, 
infarct-type necrosis, and hemorrhage are uncommon. If present, cysts may be secondary to 
necrosis and hemorrhage. Rarely, ESN may exclusively be cystic [8].
2.2. Microscopic features
ESN is composed of cells with uniform round-ovoid nuclei, small nucleoli, and scant-
moderate eosinophilic cytoplasms. This diffuse proliferation of monotonous “blue cells” 
resembles proliferative phase of endometrial stroma (Figure 1A and B). Cytological atypia 
is minimal, and although mitotic rate is usually low (up to 5 mitosis/10 HPF), a higher 
count does not exclude ESN diagnosis [8]. A rich and arborizing network of small arterioles 
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around which neoplastic cells are concentrically arranged also characterizes ESS [8]. Thick-
walled vessels may be present in a minority of cases. The presence of collagen bands or 
plaques uniformly dispersed in the context of the tumor is often seen (Figure 1A). Foamy 
histiocytes, singly or in clusters are also described, as well as cholesterol clefts. ESNs pres-
ent some variants including smooth muscle, skeletal muscle, and sex-cord stromal differ-
entiations [8].
2.3. Immunohistochemistry
Vimentin, CD10, actins, WT1, ER, and PR are typically positive in ESN. Rarely, the neo-
plasia may be CD10 negative. Although, smooth muscle tumors and ESN demonstrate an 
overlapped immunophenotype, CD10, desmin, h-caldesmon, smooth muscle heavy chain 
myosin, and HDAC8 facilitate the differential diagnosis. In particular, areas of smooth 
muscle differentiation stain positive for desmin and h-caldesmon, although areas of stromal 
differentiation may be desmin positive also; such areas show a typical perinuclear cytoplas-
mic pattern [8].
2.4. Differential diagnosis
ESN with smooth muscle differentiation can be misdiagnosed as endometrial stromal 
sarcoma invading the myometrium, due to the presence of interdigitating smooth mus-
cle cells misinterpreted as myometrial invasion [9]. Differential diagnosis would also 
be needed between ESN, highly cellular leiomyoma, LMS, and LGESS. Highly cellular 
leiomyoma characteristically shows focal fascicular pattern, margins with a cleft-like 
zone, and contains thick-walled blood vessels [8]. Uterine LMS does not present as a 
low-grade neoplasia [8]. Finally, since morphology demonstrates to be not useful in dis-
tinguishing between ESN and LGESS, diagnosis relies on the exclusion of myometrial 
and lymph vascular invasion [8]. A definitive diagnosis of ESN should be provided after 
a careful examination of tumor borders; thus, specimens from hysterectomy are needed. 
Figure 1. Endometrial stromal nodule. (A) Diffuse proliferation of monotonous blue cells resembling proliferative phase 
of endometrial stroma. Collagen bands dispersed in the context of the tumor (arrow), EE, 10×. (B) Neoplastic cells show 
uniform round-ovoid nuclei and scant-moderate eosinophilic cytoplasms, EE, 20×.
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On curettage specimens, the distinction between ESN and LGESS is quite impossible. 
Finally, in ESNs with “limited infiltration,” the infiltration is not widespread as showed 
by LGESS [8].
2.5. Molecular features
ESN is characterized by the chromosomal translocation t(7,17) (p15;q21), resulting in the for-
mation of JAZF1-SUZ12 fusion gene. JAZF1-SUZ12 gene has been found in about 50% of 
ESNs and in LGESS [10].
2.6. Keypoints
• ESN may demonstrate focal finger-like projections toward myometrium. To confirm ESN 
diagnosis, the projections should be <3 in number and <3 mm in their maximum extension.
• Both ESN and LGESS share the same genetic aberration; thus, the presence of t(7;17) cannot 
be used to distinguish between the two neoplasia.
• Correlation between immunostain results and morphology may help in distinguishing 
between ESN with smooth muscle differentiation and pure smooth muscle tumor.
3. Low-grade endometrial stromal sarcoma (LGESS)
This neoplasia is composed of cells resembling those of endometrial stroma during prolif-
erative phase, associated with a broad network of arteriolar-like vessels. The tumor shows 
infiltrative “tongue-like” growth into the myometrium, with or without lymph vascular 
invasion.
Accounting for about 0.2–1% of all uterine malignancies, LGESS represents the second 
most common uterine sarcoma. It is more common than ESN. The age range is similar 
to that of ESN, more often occurring in perimenopause. The median age is 52 years. No 
race is favorite [10]. Being a slow-growing tumor with an indolent clinical course, LGESS 
shown no-specific signs; they include vaginal bleeding and pelvic pain. LGESS most fre-
quently occurs in the uterine corpus, even if extra uterine locations such as ovary pelvis, 
abdominal cavity, vulva, and vagina are possible. Association with endometriosis has been 
described [11].
3.1. Macroscopic features
The vast majority of LGESS are diagnosed on hysterectomy that has to be considered as a 
diagnostic and therapeutic approach. Curettage or myomectomy specimens are not useful, 
since LGESS diagnosis should substantially rely on the evaluation of the tumor/myometrial 
interface [8]. Fertility-sparing approaches should be used only in carefully selected cases. 
Grossly, LGESS is typically poorly defined, but well-circumscribed borders might be found 
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when myometrial invasion is limited. Neoplastic mass may present as intracavitary or intra-
myometrial. Similarly to ESN, the cut surface is fleshy with tan-to-yellow or white color. 
Firmly consistency is reported in the presence of extensive fibrous stroma. Cystic formation, 
as well as areas of hemorrhage and necrosis might be present [8]. Rarely, LGESS appears as 
a pure cystic mass.
3.2. Microscopic features
LGESS is characterized by the irregular interface with the myometrium (Figure 2A). 
Myometrial invasion and lymph vascular “tongue-like” patterns represent the cardinal fea-
tures to put differential diagnosis between LGESS and ESN [8]. Cytological features are iden-
tical to those of ESN: monotonous “blue cells,” with scant cytoplasm, uniform oval-spindle 
nuclei, and small nucleoli, typically growing in sheets or storiform patterns (Figure 2B). Vessels 
are thin with hemangiopericytoma-like morphology or, less commonly, thick and placed at 
the periphery of the neoplasia. Nuclear atypia is not significant and mitotic count is usually 
less than 5 mitosis/10 HPF ([8], p. 1). Like in ESN, alyne bands, cholesterol clefts in the context 
of areas of necrosis, and cystic formation may be encountered. Several histological variants 
of LGESS have been described. In smooth muscle type, smooth muscle component accounts 
for more than 30% of all uterine mass [8]. On gross examination, this component appears as a 
firmly area. Microscopically, smooth muscle differentiation is characterized by pink irregular 
islands of slightly epithelioid cells. Starburst pattern, with a central area of hyalinization and 
collagen bands radiate toward the periphery, may also be seen [8]. In myxoid and fibroblas-
tic type, neoplastic background is typically hypocellular. Fibroblastic component has been 
reported in about 50% of ESS with t(10,17). In such cases, a more aggressive behavior has 
Figure 2. Low-grade endometrial stromal sarcoma. (A) Irregular interface with the myometrium, with ‘tongue-like’ 
patterns of invasion, EE, 4×. (B) Monotonous blue cells, with scant cytoplasms and uniform oval-spindle nuclei, EE, 20×. 
(C) CD10 positive stain, 20×. (D) Estrogens receptor stain, 20×. (E) MIB1 index, 10×.
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been demonstrated [8]. Sex cord-like elements, consisting in anastomosing cords, trabeculae, 
islands, nests, tubules or sheets of cells resembling the pattern typically seen in granulosa 
and Sertoli ovarian cell tumors, may also be encountered in LGESS. Sex cord-like cells are 
usually present within the endometrial stroma. Not infrequently, the areas of smooth muscle 
differentiation may also co-exist [12]. Glandular elements showing endometrioid morphol-
ogy have also been reported in LGESS. Cells have cuboid-columnar shape; with eosinophilic 
or rarely clear cytoplasm and minimal cytological atypia [1]. Epithelioid variant is charac-
terized by cells with oval-polygonal appearance and abundant, often granular, cytoplasm 
[8]. Rhabdoid type shows cells with large and eosinophilic cytoplasmic inclusions, eccentric 
vesicular nuclei, and prominent nucleoli [13].
Antibody markers LGESS HGESS UUS UTROSCT
Smooth muscle actin +, patchy +
Desmin + +, patchy +
h-cardesmon + +
EMA ± +, patchy
CD10 ++ — ±
CD34 —
CD44
Cytokeratins ± +, patchy +
HDAC8
ER + — - or weakly +
PR + — - or weakly +
p53 +
p21
Bcl-2
MIB1 high percentage
p16 +
Inhibin +
S100
c-kit +
Cyclin D1 — ± —
LGESS, low-grade endometrial stromal sarcoma; HGESS, high-grade endometrial stromal sarcoma; UUS, undifferentiated 
uterine sarcoma; and UTROSCT, uterine tumor resembling an ovarian sex-cord tumor.
Table 2. Immunohistochemical features of uterine endometrial stromal tumors.
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3.3. Immunohistochemistry
No single marker demonstrated high specificity. Thus, a panel of antibodies should be used 
(Table 2). It is also important to take into account the intensity and the distribution of posi-
tive results and to correlate them with histological features and gross findings. CD10 is a 
very helpful marker, since its expression is generally strong and diffuse in typical LGESS 
(Figure 2C). Positive stain for WT1, ER, and PR is observed in more than 80% of LGESS 
(Figure 2D) [8]. Ki67 mitotic index is high (Figure 2E). Cyclin D1 is negative or focally posi-
tive [14]. However, in t(10;17), LGESS CD10 may be negative or weakly and focally positive 
[14–27]. t(10,17) LGESSs are frequently negative for ER and PR too [15]. Expression of nuclear 
β-catenin has been reported in about 40% of t(10;17) LGESS, often in association with cyclin 
D1 positivity [15]. In general, LGESS variants show immunohistochemical pattern concor-
dant with the type of cellular differentiation [15]. Epithelioid LGESS is typically positive for 
desmin and h-caldesmon, often positive for keratin and EMA, and negative for cyclin D1 
[8]. Expression of smooth muscle actin, desmin, and h-caldesmon may be present in typical 
LGESS [8]. Since CD34 is almost never expressed in uterine LGESS, this marker is helpful to 
diagnose LGESS of extra uterine sites [15]. p53 is typically absent in LGESS, while it has been 
reported in HGESS and USS ([8], p. 1). Finally, expressions of PDGFR-α and PDGFR-β were, 
respectively, found in 50 and 42% of LGESSs [16].
3.4. Differential diagnosis
Differential diagnosis between ESN and LGESS has been previously described. A common 
problem is to differentiate LGESS from highly cellular leiomyoma. Careful macroscopic and 
microscopic assessment is needed to put the right diagnosis. Leiomyoma usually forms fas-
cicles of spindle cells with elongated cigar-shaped nuclei; blood vessels are small and do not 
show the typical arteriolar morphology usually seen in LGESS. In addition, using a panel of 
antibodies including CD10, desmin, and h-caldesmon, differential diagnosis may be facili-
tated. It would be always important to correlate immunostain results with morphology [8]. 
Both LGESS and intravenous leiomyomatosis may show vessel invasion; however, micro-
scopic examination helps to differentiate these entities, since the latter is characterized by 
a fascicular pattern with large and tick blood vessels [8]. Epithelioid smooth muscle tumor 
can resemble the smooth muscle variant of LGESS. However, the former lacks of the typi-
cal vasculature seen in the endometrial stromal neoplasia. ESS with myxoid differentiation 
may be confused with myxoid LMS, since both show hypocellularity and a similar pattern 
of myometrial infiltration. However, LMS usually demonstrates cells with high-grade atypia 
and brisk mitotic activity [8].
Distinction between LGESS with sex cord-like differentiation and Uterine Tumor 
Resembling an Ovarian Sex-Cord Tumor (UTROSCT) has to be done. UTROSCT is a rare 
mesenchymal neoplasm composed of epithelial-like cells showing the typical patterns 
of the ovary sex-cord stromal tumors; its behavior is benign, without risk of recurrences 
[17]. Differential diagnosis should rely on the presence of areas of conventional stromal 
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neoplasia in the LGESSs. Obviously, the distinction cannot be done on biopsy or curet-
tage specimens. Immunohistochemistry may be helpful when using a panel of antibodies 
including inhibin, calretinin, and Melan A [8]. Stromal component of an adenosarcoma 
may be morphologically and immunohistochemically identical to that of ESS. However, 
while the stromal component of adenosarcoma is strictly associated with the epithelial 
component, in LGESS, glands are few and randomly placed [8]. Finally, GIST comes into 
differential diagnosis with LGESS; in these cases, a panel of antibodies including c-kit and 
DOG1 should be used [18].
3.5. Molecular features
The vast majority of LGESSs harbor chromosomal rearrangements.
As previously described, the most common genetic aberration is the t(7;17) (p15;q21) trans-
location that has been found in about 80% of LGESSs and morphological variants. t(7;17) 
(p15;q21) results in JAZF1-SUZ12 gene fusion [19]. Being detected in both ESN and LGESS, 
t(7;17) translocation would represent an early event in the development of ESS. It has been 
hypothesized that ESS would originate from a benign stromal proliferation, being neoplastic 
progression the result of additional events [20]. As a counterpart, the lack of JAZF1-SUZ12 
gene in most cases of undifferentiated endometrial sarcoma would suggest the existence of 
a different pathogenesis leading to ESS. Translocation t(6;17) (p21;p22) represents the second 
most common genetic abnormality in LGESS, being the t(6p;10q,10p) the third. Other gene 
fusions, which have been detected in association with ESSs, are JAZF1/PHF1, EPC1/PHF1 
MEAF6-PHF1, ZC3H7-BCOR, and MBTD1-CXorf67 ([21], p. 109). JAZF1, SUZ12, PHF1, and 
EPC1 gene fusions have also been detected in other types of benign and malignant neoplasia 
[21]. Rearrangement of the X chromosome has also been seen in LGESS, in association with 
two different transcripts [22]. All of the genes involved in the previously listed chromosomal 
translocations are implicated in transcriptional regulation. Translocations would lead to onco-
genic effects starting from deregulation of transcriptional mechanisms in endometrial stromal 
stem cells [23]. All of the genetic fusions seem to be equivalent in inducing oncogenic events, 
since LGESSs having different genotypes show similar clinical behavior. Microscopically, all 
of the JAZF1 LGESSs demonstrate tongue-like myometrial invasion accompanied by vascu-
lar invasion [23]. From a prognostic point of view, both JAZF1-LGESS and LGESS without 
genetic rearrangements (wild LGESS) usually have a low incidence of recurrences [23]. 
Finally, although no correlation has been found between morphological variant of LGESS 
and a specific chromosomal abnormality, PHF1 genetic rearrangement has been frequently 
observed in LGESS with sex cord differentiation [24].
3.6. Therapeutic approaches
Patients with LGESS are usually treated with hysterectomy plus bilateral salpingo-oophorec-
tomy, the latest to avoid the secondary stimulation of the tumor by ovarian hormones. Younger 
patients desiring to preserve fertility can be treated with hormonal therapy or aromatase 
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inhibitors. The adjunct of gonadotropin releasing hormone (GnRH) may reduce ovarian syn-
thesis of estrogens [25]. Since low-grade ESSs show low response rates to conventional CT, 
there is no evidences supporting its use ex adiuvantibus. On the other hand, the presence of 
estrogens and progesterone receptors in about 80% of the LGESS would give the opportunity 
to reduce the recurrence rate and risk of relapse using adjuvant endocrine therapy. Hormone 
therapy with progestin, aromatase inhibitors, and analogues of the gonadotropin-releasing 
hormone has become an effective post-surgical treatment in patients with low-grade ESS [26]. 
Particularly, aromatase inhibitors are becoming the treatment of choice, since progestin is 
poorly tolerated due to side effects. The duration of hormonal therapy should be protracted 
for 3–5 years after surgery [26]. Tumors with t(10;17) translocation, typically not responding to 
conventional treatment, should be treated with a more aggressive therapy such as RT and CT 
combination [23]. Finally, in LGESS showing immunohistochemical positivity for PDGFR-α 
and PDGFR-β, the PDGF signaling pathway may be considered as a useful therapeutic target 
for imatinib [26].
3.7. Prognosis
Stage is the most significant prognostic indicator in LGESS. Disease-specific survival is 
approximately 80–90% at 5 years and 70% at 10 years [26]. Patients with stage I LGESS show a 
survival rate of about 100% at 5 years and 90% at 10 years; women presenting with high-stage 
disease have a survival rate of 40%, which is constant at 5 and 10 years [8]. Clearly, tumor 
grading is also a powerful predictor of disease recurrences, which are observed in about 50% 
of the patients especially in pelvis, abdomen, and lungs [8]. Recent data demonstrated that 
stage and mitotic activity correlate with the outcome of the neoplasia, while cytological atypia 
correlates with increased relapse of LGESSs [8]. A tumor showing both severe cytological 
atypia and high mitotic rate, with or without the typical endometrial stromal sarcoma growth 
pattern, should be considered as USS [8]. Cases of USS arising in a background of LGESS have 
been rarely reported [27]. A tumor with more than 10 mitotic figures/10 HPF without severe 
cytological atypia should be considered as a pure LGESS. Finally, prognosis of JAZF1-LGESS 
and wild-LGESS are similar, since no genotype-specific target therapy exists yet [25].
3.8. Keypoints
• Like ESN, LGESS may be well circumscribed on gross examination. Thus, the adequate 
sampling of the interface neoplastic border/myometrium is imperative to reach a correct 
diagnosis.
• Biopsy, curettage or myomectomy specimens are not useful.
• Cytological features of LGESS are identical to those of ESN. Nuclear atypia is not signifi-
cant, mitotic rate is usually less than 5 mitosis/10 HPF, nuclear pleomorphism is absent, 
and necrosis is rarely present.
• A panel of antibody may help in diagnosis, in tight correlation with gross and microscopi-
cal features. In LGESS, cyclin D1 is negative-to-focal, and CD10 and ER/PR are diffusely 
positive.
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• LGESS demonstrate histological variants.
• Since sex cord-like differentiation may occur in LGESS, UTROSCT should be excluded by 
extensive samples.
• Intravenous leiomyomatosis can be highly cellular and often mimics a LGESS. Intravascular 
component with cleft-like spaces, fascicular growth pattern, proliferation of spindle cells 
colonizing the wall of the veins, and thick-walled blood vessels may help to diagnose the 
former.
• The most common chromosomal translocation in LGESS is t(7;17) (p15;q21), resulting in 
JAZF1-SUZ12 gene fusion.
• Stage and brisk mitotic activity correlate with the outcome, while cytological atypia cor-
relates with increased relapse.
4. High-grade endometrial stromal sarcoma (HGESS)
The 2014 WHO classification of uterine mesenchymal tumors re-introduced HGESS as a distinct 
entity [28]. Lee et al. identified a fusion between the tyrosine 3/tryptophan5-monooxygenase 
gene YWHAE from chromosome 17p13 and the NUT family member gene NUTM (previously 
known as FAM22) from chromosome 10q22 [29]. The identification of the YWHAENUTM2A/B 
(also designed as YWHAE-FAM22A/B) gene fusion as a recurrent genetic event in ESS with 
more aggressive behavior, provided the basis to create a category of ESS intermediate between 
LGESS and UUS (Table 3). Before 2014, HGESS was enclosed in the “undifferentiated endo-
metrial sarcomas” group [30]. Kurihara et al., underlining the heterogeneity of this group, 
emphasized the importance to distinguish between tumors with nuclear uniformity and 
YWHAE rearrangement, and tumors with nuclear pleomorphism, more complex karyotypes, 
and frequent p53 alterations [8]. Separation between LGESSs and HGESSs was also important, 
due to the peculiar clinical aggressiveness of the latter [31]. The age of women affected by 
HGESS ranges from thirty to seventy years, with a mean of 50 years. HGESS most commonly 
presents with abnormal uterine bleeding and symptoms related to extra-uterine spreads [8].
ESS USS
Age at presentation Perimenopausal Postmenopausal
Cytology Monomorphous Polymorphic and highly atypical
Growth pattern Infiltrative Expansive
Vascular pattern Intravascular growth Vascular invasion
Hormonal receptors Estrogens-related Not estrogens-related
Prognosis Good, late recurrence Poor, early recurrence and distant metastasis
ESS, endometrial stromal sarcoma; USS, undifferentiated uterine sarcoma.
Table 3. Differential diagnosis between endometrial stromal sarcomas and undifferentiated uterine sarcomas.
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4.1. Macroscopic features
HGEESs appear as an intracavitary polyp or poorly circumscribed mural plaques-like masses, 
with a median diameter of 7.5 cm. The cut surface is fleshy and often associated with areas of 
hemorrhage and necrosis [8]. Being destructive, myometrial invasion of HGESS is different 
from that of LGESS, which is permeative. Extrauterine extension is frequent [8].
4.2. Microscopic features
At low-power magnification, the morphology of HGESS does not exactly look like the prolif-
erative endometrium. HGESS is characterized by a monomorphic proliferation of round cells 
arranged in a vaguely nested or pseudo-glandular pattern [8]. The infiltrative growth pattern 
and the vascularization typical of the LGESSs coexist, together with the features of destructive 
invasion of the outer half of the myometrium. The tumor often contains both morphologically 
low- and high-grade areas. Low-grade areas are hypocellular and composed by a uniform 
population of neoplastic spindle cells, with no apparent nuclear pleomorphism [8]. These 
areas may also show myxoid appearance. High-grade areas typically show a population of 
closely packed large (epithelial-like) cells, arranged in nests or cords (Figure 3A). The vascu-
lar pattern is delicate and arborized (Figure 3B) and is different from the spiral arteriolar-like 
pattern characteristically seen in LGESS. Concentric arterioles may occasionally be present 
[8]. At high magnification, HGESS cells show eosinophilic cytoplasms; nuclei are large, with 
irregular contours and prominent nucleoli (Figure 3A and C). Mitotic activity is brisk. In non-
rearranged (wild) HGESS, mitotic count is <5 mitosis/10 HPF, while YWHAE-HGESS shows 
mitotic rate > 10 mitoses/10 HPF. Coagulative necrosis is absent in wild tumors and present, 
together with lymph vascular invasion, in rearranged HGESS [8]. Rearranged HGESS always 
demonstrates uniform high-grade cytomorphology, although high-grade morphology is not 
always associated with YWHAE genetic rearrangement [32].
4.3. Immunohistochemistry
Low- and high-grade components of HGESS have a different immunohistochemical profile [8]. 
The low-grade component, similarly to LGESS, stains positive for CD10, ER, and PR. Cyclin D1 
is negative-to-focal in rearranged HGESS, while it is diffusely positive in wild neoplasia. CD117 
Figure 3. High-grade endometrial stromal sarcoma. (A) High-grade area: proliferation of closely packed large cells with 
eosinophilic cytoplasms, large nuclei and prominent nucleoli. Cells are arranged in cord pattern, EE, 20×. (B) Delicate 
and arborized vascular pattern (square), EE, 4×. (C) Pleomorphism and nuclear atypia, 40×.
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stains negative [8]. The high-grade component is negative for CD10, ER, and PR in wild tumors 
and positive in rearranged HGESS [8]. Lack of expression for hormones receptors would have 
potential treatment implications. CD117 is often positive (Table 2) [8]. The different morpho-
logical and immunohistochemical features of HGESS may be considered as a surrogate indica-
tor for the underlying genetic rearrangement, even if both fluorescence in situ hybridization 
(FISH) and reverse transcriptase-PCR (RT-PCR) demonstrated to be more useful [33].
4.4. Differential diagnosis
Adequate sampling is always necessary to diagnose HGESS, since approximately 50% of 
these tumors contain a low-grade component, which overlaps with LGESS [8]. Low-grade 
component shows smaller “blue” cells with scanty cytoplasm and smooth nuclear contour, 
spiral arterioles, infrequent necrosis, positivity for CD10, ER, PR, and negativity for cyclin D1 
and c-kit. Moreover, it lacks of biphasic appearance. Differential diagnosis between HGESS 
and epithelioid LMS should be based on the lacking of a prominent delicate vasculature in 
the latter. In addition, HGESS does not show a marked atypia. LMS is typically positive for 
desmin, caldesmon, ER, and PR, but negative (or only focally positive) for cyclin D1 [8]. To 
differentiate HGESS with intraperitoneal/pelvic locations from GIST, DOG1 antibody is help-
ful, since it always lack in the former [34].
4.5. Molecular features
As previously shown, genetic fusion YWHAE-FAM22 is characteristic of ESS with high-
grade histological features. FISH analysis demonstrated the absolute specificity of YWHAE-
FAM22A/B rearrangement in HGESS, since fusion gene has been detected neither in other 
uterine sarcomas nor in extra-uterine mesenchymal tumors [34]. FISH demonstrated higher 
sensitivity than RT-PCR in detecting YWHAE-FAM22A/B rearrangement. Croce et al. estab-
lished that the cut-off of rearranged cells to consider FISH as positive should be 30%; they also 
recommended to add RT-PCR in borderline cases [35]. Such molecular evidences surely will 
have diagnostic and therapeutic implications [35].
4.6. Therapeutic approaches
Due to the lack of ER and PR receptors, anti-estrogenic therapy seems to be inappropriate in 
controlling HGESS growth. Adjuvant CT may provide survival benefit, although experiences 
are limited [35]. Overexpression of EGFR and Erbb2 has been reported in both HGESS and 
UUSS. In these cases, treatment with imatinib or trastuzumab may be an option [36]. Recently, 
overexpression of c-kit has been reported in HGESS carrying the YWHAE/FAM22A/B gene 
fusion. In these cases, a response to imatinib was also described [36].
4.7. Prognosis
Patient with HGESS typically present with advanced stage disease (stages II–IV). Moreover, 
in comparison to LGESS, patients with HGESS have earlier (within 1 year after initial sur-
gery) and more frequent recurrences. Particularly, in terms of prognosis, YWHAE-rearranged 
HGESS is intermediate between LGESS and UUS [37].
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4.8. Keypoints
• Myometrial invasion is destructive in HGESS and permeative in LGESS.
• HGESS may morphologically show low- and high-grade areas. Low-grade areas are hypo-
cellular and composed by neoplastic spindle cells, with no nuclear pleomorphism. High-
grade areas show round-epithelioid cells.
• Vascular pattern is delicate and arborized.
• It is extremely important to distinguish between rearranged YWHAE HGESS and wild 
HGESS.
• Mitotic activity in rearranged tumors is <5 mitosis/10 HPF, while it is >10 mitosis/10HPF in 
wild neoplasia. Coagulative necrosis is absent in the former and present in the latter.
• Mitotic rate should not be used as the unique criterion to distinguish between LGESS and 
HGESS.
• Distinction between LGESS and HGESS is clinically relevant, since patients with HGESS 
would have a more aggressive course.
• Cyclin D1 is negative-to-focal in rearranged HGESS and diffusely positive in wild tumors. 
Immunohistochemistry with CD10 and ER/PR antibodies shows positive results in YWHAE 
HGESS and negative results in wild HGESS. Due to the lacking of ER/PR receptors, hor-
monal treatment is not useful in wild neoplasia.
• Because of the frequent positivity for c-kit antibody in both HGESS and GIST, this marker 
shows low sensitivity. Vice versa, DOG1 is more specific.
• YWHAE-FAM22 fusion gene is characteristic of HGESSs, which show high-grade histo-
logical features.
5. Undifferentiated uterine sarcoma (UUS)
In 2014, WHO re-classified gynecological tumors and replaced the old terminology of 
Undifferentiated Endometrial Sarcoma (UES) with UUS [28]. UUS represents a diagnosis of 
exclusion, referring to a high-grade sarcoma, which lacks a specific mesenchymal differentia-
tion. UUSs may also enclose poorly differentiated LMS in which smooth muscle cells have been 
completely replaced by the sarcomatous component [28]. UESs are rare and highly aggressive; 
they present as intramural mass or intracavitary polyps [8]. Signs and symptoms are non-specific 
enclosing abnormal uterine bleeding, pelvic mass, or pain due extra-uterine spreads. USS typi-
cally occurs in older postmenopausal women [8]. The occurrence of cases with coexisting LGESS 
component would suggest that USS might also arise from a dedifferentiation of a LGESS [8].
5.1. Macroscopic features
Grossly, cut surface is tan to white, with fleshy consistency. Hemorrhage and necrosis are 
common [8].
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5.2. Microscopic features
UUS shows a combination of severe nuclear atypia, brisk high mitotic rate, and tumor 
cell necrosis (Figure 4A) ([8], p. 1). Histologically, UUS can be distinguished into two 
histologic variants: uniform UUS (u-UUS) and pleomorphic UUS (p-UUS) [8]. u-UUSs 
show morphologic and immunophenotypic characteristics of HGESS, and frequently har-
bor t(10,17) rearrangement [38]. p-UUSs show destructive infiltration of the myometrium 
(Figure 4B), highly pleomorphic cells and a fascicular growth pattern not resembling pro-
liferative endometrial stroma [39, 40]. Lymph vascular invasion is common (Figure 4C 
and D) [41].
5.3. Immunohistochemistry
Being undifferentiated by definition, the immunohistochemical characterization of UUS it 
sometimes hard and reflects the heterogenicity of this category of tumors. USSs are typically 
CD10, p53, and cyclin D1 positive (Figure 4E); ER and PR usually stain negative or weakly 
positive [42]. Desmin, EMA, and keratins may show focal positivity (Figure 4F). Smooth 
muscle actin may be focally positive, although the presence of positive stain for more than one 
smooth muscle marker should drive to a suspect of LMS [42]. On the other hand, a positive 
Figure 4. Undifferentiated uterine sarcoma. (A) Tumor-cell necrosis, EE, 4×. (B) Destructive infiltration of the 
myometrium), EE, 4×. (C) Vascular pattern, EE, 10×. (D) Lymph-vascular invasion with embolism, EE, 20×. (E) CD10 
stain, 20×. (F) Desmin stain, 10×. (G) MIB1 index, 10×.
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stain for keratin and EMA should lead to the suspicion of undifferentiated endometrial carci-
noma [42]. MIB1 index is usually high (Figure 4G).
5.4. Differential diagnosis
Being a diagnosis of exclusion, the suspect of USS should be put after an extensive sampling of 
the neoplastic mass. Differential diagnosis includes: leiomyosarcoma or rhabdomyosarcoma, 
which typically show marked cytological atypia and positivity for desmin, h-caldesmon, ker-
atins, and EMA; carcinosarcoma that presents a malignant epithelial component; müllerian 
adenosarcoma, where benign epithelial cells may be encountered; malignant mixed müllerian 
tumor, in which the epithelial component is limited [8].
5.5. Molecular features
Genetically, little is known about UUS. In the vast majority of the cases, it has been demon-
strated a genetic pathways that is different from those of LGESS and HGESS, although it is 
not specific (i.e., complex karyotypes, genomic gains, and losses). Particularly, gains of 2q, 
4q, 6q, 7p, 9q, 20q and losses of 3q, 10p, and 14q have been detected. A subset of USSs also 
demonstrated a missense TP53 mutation [15].
5.6. Therapeutic approaches
Patients should be treated with radical hysterectomy and bilateral salpingo-oophorectomy. 
Adjuvant RT and/or CT are strongly suggested [43].
5.7. Prognosis
Due to their aggressiveness, USSs are associated with a poor prognosis, with an overall sur-
vival <2 years [43].
5.8. Keypoints
• USS is a diagnosis of exclusion, lacking of smooth muscle or endometrial stromal 
differentiation.
• USS diagnosis should be made by extensive sampling of the neoplastic mass, following 
hysterectomy.
• Histologically, UUS can be distinguished into two histologic variants: uniform UUS and 
pleomorphic UUS.
• USS is typically CD10, p53, and cyclin D1 positive, while ER and PR are negative or weakly 
positive. Desmin, EMA, and keratins may show focal positivity.
• USS lacks of a specific molecular pathway, although genetic rearrangements, different 
from those of LGESSs and HGESSs, have been detected.
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6. Imaging in ESS diagnosis
Even if imaging cannot reliably help to diagnose an ESS before surgery, some specific character-
istics can be identified. On US, the neoplastic mass is hypoechogenic, with irregular margins. By 
Doppler, vascularization pattern appears as irregular. On MRI, ESS typically presents as an inva-
sive endometrial mass with wide myometrial involvement and extension along vessels and/or liga-
ments. ESS also shows intense 18 FDG uptake. The combination of PET and CT demonstrated to be 
promising for diagnosis [8]. Due to the high incidence of distant metastases at the first presentation, 
preoperative imaging of the chest and abdomen may be considered when ESS is suspected [8].
7. Therapeutic approaches
7.1. Surgery
Hysterectomy represents the best practice to treat localized ESS. Since ESS typically expresses 
ER and PR, there would be a higher risk of recurrence if the ovaries are retained; thus, in post-
menopausal women, salpingo-oophorectomy should be performed [8]. Tumor morcellation, 
a widespread technique used for presumed benign disease, demonstrated to have an adverse 
impact on patient’s outcome [8]. The benefit of lymphadenectomy in ESS is still controversial. 
The incidence of lymph node metastases is generally low, but it is common in higher stages 
of disease thus resulting in a worse outcome. Overall, systematic lymphadenectomy does not 
appear to confer a therapeutic benefit. The role of cytoreductive surgery in locally advanced 
ESS is controversial. Finally, the resection of distant metastases and cytoreductive procedures 
should be performed in case of recurrent ESS [27].
7.2. Other therapies
7.2.1. Hormonal therapy
The high rate of positive results for hormones receptors has led to interest in using adjuvant 
hormonal therapy for both early stage and advanced LGESS. Hormonal therapies are gener-
ally well tolerated, even if several questions remain controversial, such as doses, regimens 
(i.e., progestins, gonadotrophin-releasing hormone agonists, and aromatase inhibitors), and 
duration of therapy. In general, the lack of significant adverse effects would allow the admin-
istration for longer periods. Hormonal therapies seem to be effective for metastatic disease 
also. Conversely, the frequent lack of ER and PR in HGESS and UUS makes the hormonal 
therapy ineffective in controlling tumor growth [42].
7.2.2. Chemotherapy
Findings regarding the ESS response to CT are scarce, since data from high-grade and low-
grade ESS are pooled. In general, the rate of response to CT is low; thus, it should only be used 
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when hormonal therapies have become ineffective [42]. Anthracycline and/or ifosfamide are 
presently considered in the first-line therapeutic regimen [41].
7.2.3. Radiotherapy
Although postoperative RT demonstrated some benefits in controlling loco-regional disease, 
overall survival is rarely improved, since ESSs typically recur distantly. In recurrent or meta-
static ESS, palliative radiotherapy is usually used to reduce symptoms [41].
8. Prognostic factors and survival
JAZF1-LGESSs and LGESSs with no demonstrable genetic rearrangements (wild LGESSs) 
generally show stage 1 at presentation. Their prognosis is excellent with a low risk of recur-
rence [41]. In comparison, YWHAE–NUTM2 ESSs typically present in advanced stages (stages 
2–4); they frequently recur within a few years after the initial surgery [42].
9. Rare sarcomas
9.1. Rhabdomyosarcoma
It is most common in the uterine cervix than in the uterine corpus. Patients typically presents 
with abnormal postmenopausal bleeding. Uterine mass is typically polypoid, with a fleshy 
cut surface and areas of hemorrhage and necrosis. Microscopically, sheets of atypical cells 
with abundant and eosinophilic cytoplasms, large pleomorphic nuclei, and atypical mitosis 
are seen. Rhabdomyosarcoma stains positive for muscle specific actin and desmin, but it is 
negative for smooth muscle actin. Expression of WT1, S100, EMA, and keratins is uncommon. 
The treatment relies on surgery and CT, with or without RT. Adult age, extracervical location, 
pleomorphism, depth invasion, and distant metastasis are all bad prognostic factors [8].
9.2. Alveolar soft part sarcoma
It frequently arises in uterine cervix of adolescent and young women. Microscopically, alve-
olar and organoid patterns separated by delicate fibrovascular septa are seen. Cells show 
abundant and eosinophilic cytoplasms and contain PAS-positive diastase resisting granules 
or crystals. Nuclei are large and vesicular, with evident nucleoli. Mitosis is rare. The neoplasia 
typically shows strong TFE3 positivity. Vimentin, smooth muscle markers, CD10, S100, NSE, 
and HMB45 may also be positive. Surgery represents the elective treatment [8].
9.3. Angiosarcoma
It presents as a hemorrhagic and diffusely infiltrating mass, often simulating a leiomyoma [8]. 
Neoplastic cells show vascular differentiation; they stain positive for the vascular endothelial mark-
ers CD31, CD34, cyclin D1, and vimentin. The lymphatic endothelial marker D2-40 is absent [8].
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9.4. Liposarcoma
The fat cell tumors of the uterus are extremely rare, showing an incidence of 0.03–0.2%. The 
histogenesis of this tumor is not completely clear. The theory of “tumor metaplasia” has been 
postulated. Uterine liposarcoma shows an aggressive behavior [8].
10. Conclusions
The in-depth investigations of US biology have certainly improved the therapeutic 
approaches to these malignancies. Presently, a great number of agents are under investiga-
tion. TKI, mTOR inhibitors, growth factors/growth factor receptor inhibitors and antian-
giogenic agents, represent the most promising drugs. SARC028 and the anti-PD1 antibody 
pembrolizumab (also called MK.3475) for advanced sarcomas, and nivolumab plus ipilim-
umab for patients with unresectable sarcoma, are in phase II trials [43]. Pazopanib (a selec-
tive multi-targeted inhibitor of tyrosine kinase receptors), trabectedin, and eribulin have 
been recently approved. On the other side, immunotherapy did not show potential benefits 
for US. It is our opinion that future genetic research will significantly allow a better identifi-
cation of the molecular signatures of US, in order to provide the optimal treatment strategy 
for these malignancies [43–48].
At the end of the present work, which represents the effort to synthesize all of the updated 
findings on US, we need to emphasize the importance of interdisciplinary approach to achieve 
the correct diagnosis and the optimal management for this neoplasia.
The availability of clinical and laboratory information, as well as pharmacological anamne-
sis, would allow pathologist to put the correct diagnosis of US. Moreover, the continuous 
research of novel therapeutic approaches would guarantee the updated management of these 
malignancies.
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